|
|
|
Hair Loss Study Abstract: A comparative study of a new food supplement, ViviScal, with fish extract for the treatment of hereditary androgenic alopecia in young males
|
Title
A comparative study of a new food supplement, ViviScal, with fish extract for the
treatment of hereditary androgenic alopecia in young males [published erratum appears in J
Int Med Res 1993 Jan-Feb;21(1):following 65]
Author
Lassus A, Eskelinen E
Address
Department of Dermatological Research, ARS-Medicina, Helsinki, Finland.
Source
J Int Med Res, 20: 6, 1992 Nov, 445-53
Abstract
A controlled, randomized, double-blind, parallel-group study compared the effects of
ViviScal (a new food supplement incorporating special marine extracts and a silica
compound) with those of a fish extract in the treatment of young males with hereditary
androgenic alopecia. The pretreatment histological diagnosis was alopecia with a mild to
moderate perifollicular inflammation zone. The study consisted of 20 subjects who received
two tablets of ViviScal once daily and 20 who received two tablets of fish extract once
daily for 6 months. The mean patient age and mean duration and severity of baldness
compared well between the two groups. Most patients had been treated with long-term
topical 2% minoxidil for 1 year or more prior to the study. At baseline and after 6
months' treatment, a biopsy was taken for histological examination. A non-vellus hair
count was performed at baseline and after 2, 4 and 6 months. In the fish extract treatment
group three patients withdrew from the study before the fourth month due to lack of
therapeutic effect. After 6 months' treatment, patients receiving ViviScal showed a mean
increase in non-vellus hair of 38% compared with a 2% increase in the fish extract
treatment group (P < 0.0001). In the ViviScal group, 19 (95%) subjects showed both
clinical and histological cure, whereas None treated with fish extract showed any clinical
or histological difference after 6 months' treatment (P < 0.0001). In both groups, a
minimal decrease in the erythemal index was observed. In conclusion, ViviScal appears to
be the first highly active treatment for androgenic alopecia in young males.
Language of Publication
English
Unique Identifier
93162288
content2 |
|
